John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the International League Against Epilepsy

Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring Volume 18, numéro 4, December 2016

Illustrations

  • Figure 1
  • Figure 2

Tableaux

Auteurs
1 Programme for Pharmacy, Dept. of Life Sciences and Health, Oslo and Akershus University College of Applied Sciences, Oslo, Norway
2 The National Center for Epilepsy, Sandvika, Oslo University Hospital, Norway
3 Dept. of Pharmacology, Oslo University Hospital, Norway
4 Dept. of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
* Correspondence: Cecilie Johannessen Landmark Programme for Pharmacy, Dept. of Life Sciences and Health, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences, Pilestredet 50, N-0167 Oslo, Norway
  • Mots-clés : lessons from history, antiepileptic drugs, dosing strategies, efficacy, individualisation, pharmacokinetic variability, tolerability, therapeutic drug monitoring
  • DOI : 10.1684/epd.2016.0880
  • Page(s) : 367-83
  • Année de parution : 2016

This review focuses on the evolution of approaches to dosing of antiepileptic drugs (AEDs) in clinical practice through history. There has been a shift in the view of treatment of epilepsy, from “one dose fits all patients” in the early days to individualisation of treatment. Over the past 50 years, our knowledge of pharmacological variability of AEDs has markedly increased through implementation of therapeutic drug monitoring (TDM). The use of TDM has demonstrated extensive pharmacokinetic variability for AEDs and a need to individualise the treatment for an optimal outcome. Factors that contribute to pharmacokinetic variability include external factors (including food and comedication), physiological factors (gender, age, and pregnancy), pathological conditions (organ dysfunction), and genetic factors (polymorphisms in metabolising enzymes). Patient groups of children, pregnant women, and the elderly, in whom the most extensive pharmacokinetic changes occur, need special attention and close follow-up of treatment. Patients with complicated and changing combination treatments are also vulnerable. Therapeutic drug monitoring may be particularly helpful in such situations. There are also challenges regarding the use and misuse of therapeutic drug monitoring, such as the use of drug monitoring without a clear indication, misinterpretation of the reference range, and erroneous sampling times.